Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.32 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | PI4KA | P42356 | 1/20 | 0.31 |
| ▸ | XDH | P47989 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.31 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.31 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8083818 | 0.98 | MEN1 (0.33) | MEN1CSNK2A2RAB9ACSNK2BCSNK2A1 | |
| Hydrochloric Acid SCHEMBL4242836 | 0.76 | PDPK1 (0.34) | — | |
| SCHEMBL10579996 | 0.73 | PDPK1 (0.35) | — | |
| SCHEMBL129804 | 0.72 | PDPK1 (0.37) | MEN1CSNK2A2RAB9ACSNK2BCSNK2A1 | |
| Adenine SCHEMBL27754928 | 0.72 | PI4KA (0.47) | LMNADRD3PI4KAXDHLRRK2 | |
| SCHEMBL13014 | 0.72 | CSNK2A2 (0.40) | MEN1CSNK2A2RAB9ACSNK2BCSNK2A1 | |
| SCHEMBL31139534 | 0.72 | CSNK2A2 (0.40) | MEN1CSNK2A2RAB9ACSNK2BCSNK2A1 | |
| Adenine SCHEMBL11342620 | 0.71 | PI4KA (0.45) | LMNADRD3PI4KAXDHLRRK2 | |
| Adenine SCHEMBL3416954 | 0.70 | PI4KA (0.48) | LMNADRD3PI4KAXDHLRRK2 | |
| Adenine SCHEMBL8110 | 0.70 | PI4KA (0.48) | LMNADRD3PI4KAXDHLRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220033432-A1 | ANTI-HEPATITIS B VIRUS AGENT | DAIKIN INDUSTRIES, LTD. (JP) | 2022-02-03 | — | — | US | disclosed |
| EP-3939655-A1 | ANTI-HEPATITIS B VIRUS AGENT | DAIKIN INDUSTRIES, LTD. (JP) | 2022-01-19 | — | — | EP | disclosed |
| WO-2020184677-A1 | ANTI-HEPATITIS B VIRUS AGENT | ダイキン工業株式会社 | 2020-09-17 | — | — | WO | disclosed |
| US-20060122291-A1 | Phase change inks containing bis(urea-urethane) compounds | XEROX CORPORATION | 2006-06-08 | — | — | US | disclosed |
| US-6835833-B2 | Alkylated tetrakis(triaminotriazine) compounds and phase change inks containing same | XEROX CORPORATION | 2004-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033432-A1 | ANTI-HEPATITIS B VIRUS AGENT | SLC10A1, HAVCR2, FABP1 | MEN1 3422/4885CSNK2A2 1692/4885RAB9A 1881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.